Dose-dependent Pharmacokinetics and Cancer Chemotherapy

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 1981 Jan 1

PMID 7023712

Citations 10

Authors

G Powis

M M Ames

J S Kovach

Affiliations

Soon will be listed here.

Abstract

Dose-dependent pharmacokinetics have been reported more frequently for anticancer drugs than for other drugs, probably because anticancer drugs are studied over a wide range of doses during early evaluation and because of the increasing use of anticancer drugs at very high doses. Dose-dependent pharmacokinetics are reflected most commonly as an increase in the biological half-life of a drug and a greater than proportional increase in plasma concentration of the drug and in area under the drug concentration-time curve with increase in dose. Occasionally the rate of drug removal increases with increasing dose. These nonlinear changes in drug concentrations with dose may lead to increases in toxicity out of proportion to increases in dose. Appreciation of the possibility of dose-dependent pharmacokinetics is important in the clinical pharmacologic evaluation of new drugs, and may be essential for the design of effective therapeutic regimens.

Citing Articles

Time- and Concentration-Dependent Adverse Effects of Paclitaxel on Non-Neuronal Cells in Rat Primary Dorsal Root Ganglia.

Elfarnawany A, Dehghani F Toxics. 2023; 11(7).

PMID: 37505547 PMC: 10385404. DOI: 10.3390/toxics11070581.

Piperine analogs arrest c-myc gene leading to downregulation of transcription for targeting cancer.

Pandya N, Kumar A Sci Rep. 2021; 11(1):22909.

PMID: 34824301 PMC: 8617303. DOI: 10.1038/s41598-021-01529-3.

Population pharmacokinetics of favipiravir in patients with COVID-19.

Irie K, Nakagawa A, Fujita H, Tamura R, Eto M, Ikesue H CPT Pharmacometrics Syst Pharmacol. 2021; 10(10):1161-1170.

PMID: 34292670 PMC: 8420316. DOI: 10.1002/psp4.12685.

The bioavailability and dose dependency of the deuterated anti-tumour agent 4,6-benzylidene-d1-D-glucose in mice and rats.

Dunsaed C, Dornish J, Pettersen E Cancer Chemother Pharmacol. 1995; 35(6):464-70.

PMID: 7882455 DOI: 10.1007/BF00686830.

Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Robert J, Hoerni B, Vrignaud P, Lagarde C Cancer Chemother Pharmacol. 1983; 10(2):115-9.

PMID: 6831624 DOI: 10.1007/BF00446222.

References

Jayaram H, Tyagi A, Anandaraj S, Montgomery J, Kelley J, Kelley J . Metabolites of alanosine, an antitumor antibiotic. Biochem Pharmacol. 1979; 28(24):3551-66. DOI: 10.1016/0006-2952(79)90400-3. View

Levy G . Pharmacokinetics of salicylate elimination in man. J Pharm Sci. 1965; 54(7):959-67. DOI: 10.1002/jps.2600540703. View

Woodcock T, Martin D, Damin L, Kemeny N, Young C . Combination clinical trials with thymidine and fluorouracil: a phase I and clinical pharmacologic evaluation. Cancer. 1980; 45(5 Suppl):1135-43. DOI: 10.1002/1097-0142(19800315)45:5+<1135::aid-cncr2820451318>3.0.co;2-q. View

Creasey W, McIntosh L, Brescia T, Odujinrin O, Aspnes G, Murray E . Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res. 1976; 36(1):216-21. View

Jenne J, Wyze M, Rood F, Macdonald F . Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline. Clin Pharmacol Ther. 1972; 13(3):349-60. DOI: 10.1002/cpt1972133349. View

Lee S, GIOVANELLA B, STEHLIN Jr J . Selective lethal effect of thymidine on human and mouse tumor cells. J Cell Physiol. 1977; 92(3):401-5. DOI: 10.1002/jcp.1040920308. View

HENDERSON E, Adamson R, OLIVERIO V . The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man. Cancer Res. 1965; 25(7):1018-24. View

Grochow L, Colvin M . Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 1979; 4(5):380-94. DOI: 10.2165/00003088-197904050-00004. View

Mukherjee K, HEIDELBERGER C . Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14. J Biol Chem. 1960; 235:433-7. View

10.

El Darrer S, Tillery K, Hill D . Distribution and metabolism of 2-amino-1,3,4-thiadiazole in mice, dogs, and monkeys. Cancer Treat Rep. 1978; 62(1):75-83. View

11.

Erlichman C, Strong J, Chabner B . Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans. Cancer Res. 1980; 40(6):1902-6. View

12.

Creaven P . Pharmacokinetic parameters: potential for and problems with their use as predictors of response to cancer chemotherapeutic agents. Bull Cancer. 1979; 66(1):85-8. View

13.

Martin B . Kinetics of elimination of drugs possessing high affinity for the plasma proteins. Nature. 1965; 207(5000):959-60. DOI: 10.1038/207959a0. View

14.

Ames M, Powis G, Kuehn P . Determination of pyrazoloimidazole in plasma and urine by gas-liquid chromatography using nitrogen-phosphorus detection. J Chromatogr. 1979; 169:412-5. DOI: 10.1016/0021-9673(75)85072-2. View

15.

Loo T, Friedman J, Moore E, Valdivieso M, Marti J, Stewart D . Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans. Cancer Res. 1980; 40(1):86-90. View

16.

Houghton G, Richens A . Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients. Br J Clin Pharmacol. 2012; 1(2):155-61. PMC: 1402453. DOI: 10.1111/j.1365-2125.1974.tb00225.x. View

17.

Huffman D, Wan S, AZARNOFF D, Hogstraten B . Pharmacokinetics of methotrexate. Clin Pharmacol Ther. 1973; 14(4):572-9. DOI: 10.1002/cpt1973144part1572. View

18.

Cohen J, Jao J . Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat. J Pharmacol Exp Ther. 1970; 174(2):206-10. View

19.

Meffin P, Robert E, Winkle R, Harapat S, Peters F, Harrison D . Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm. 1979; 7(1):29-46. DOI: 10.1007/BF01059439. View

20.

Cohen H, Jaffe N . Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate. Cancer Chemother Pharmacol. 1978; 1(1):61-4. DOI: 10.1007/BF00253148. View